Janus Kinase Inhibitors: A New Tool for the Treatment of Axial Spondyloarthritis

Marino Paroli; Rosalba Caccavale; Maria Pia Paroli; Luca Spadea; Daniele Accapezzato

doi:10.3390/ijms24021027

Janus Kinase Inhibitors: A New Tool for the Treatment of Axial Spondyloarthritis

Int J Mol Sci. 2023 Jan 5;24(2):1027. doi: 10.3390/ijms24021027.

Authors

Marino Paroli¹, Rosalba Caccavale¹, Maria Pia Paroli², Luca Spadea³, Daniele Accapezzato¹

Affiliations

¹ Division of Clinical Immunology, Department of Clinical, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy.
² Eye Clinic, Department of Sense Organs, Sapienza University of Rome, 00185 Rome, Italy.
³ Post Graduate School of Public Health, University of Siena, 53100 Siena, Italy.

Abstract

Axial spondyloarthritis (axSpA) is a chronic inflammatory disease involving the spine, peripheral joints, and entheses. This condition causes stiffness, pain, and significant limitation of movement. In recent years, several effective therapies have become available based on the use of biologics that selectively block cytokines involved in the pathogenesis of the disease, such as tumor necrosis factor-α (TNFα), interleukin (IL)-17, and IL-23. However, a significant number of patients show an inadequate response to treatment. Over 10 years ago, small synthetic molecules capable of blocking the activity of Janus kinases (JAK) were introduced in the therapy of rheumatoid arthritis. Subsequently, their indication extended to the treatment of other inflammatory rheumatic diseases. The purpose of this review is to discuss the efficacy and safety of these molecules in axSpA therapy.

Keywords: JAK inhibitors; Janus kinases; axial spondyloarthritis.

Publication types

Review

MeSH terms

Arthritis, Rheumatoid* / drug therapy
Axial Spondyloarthritis*
Humans
Janus Kinase Inhibitors* / pharmacology
Janus Kinase Inhibitors* / therapeutic use
Spondylarthritis* / drug therapy
Spondylitis, Ankylosing*

Substances

Janus Kinase Inhibitors

Grants and funding

This research received no external funding.